Healthy Volunteers Clinical Trial
Official title:
A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product GamEvac-Lyo, Vector-Based Vaccine Against Ebola Virus Disease, Lyophilisate for Preparation of Solution for Intramuscular Injection
The purpose of this study is to evaluate immunogenicity and safety of medicinal product GamEvac-Lyo- Vector-Based Vaccine against Ebola Virus Disease
Status | Completed |
Enrollment | 220 |
Est. completion date | December 31, 2018 |
Est. primary completion date | November 30, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - males and females within the age range from 18 to 55 years; - written informed consent; - subject body mass index (BMI): 18.5 = BMI = 30 - subject agrees to use effective contraceptive methods during the entire period of participation in the study (one of the following methods will be used: sexual abstinence; condoms (male or female with or without spermicidal agent); diaphragm or cervical cap with spermicidal agent; intrauterine device); - absence of severe allergic diseases in the medical history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum disease) - absence of allergic diseases relapses - absence of acute infectious diseases/relapses of chronic diseases at the time of vaccine administration and 7 days prior to the vaccination - no serious post-vaccination complications in patient's history following the earlier administration of immunobiological products - in medical history and based on the screening results, subject has no diseases of the gastrointestinal system, liver, kidneys, cardiovascular system, CNS, locomotion system, urogenital and endocrine systems that could affect the assessment of the study results - subject has a negative result of the blood or urine pregnancy test (for females of childbearing age) - subject has negative tests for HIV, hepatitis B and ?, syphilis - subject has a negative result of the urine test for residual narcotic drugs - subject has no hematopoietic malignancies - subject has no malignant neoplasms - indicators of complete blood count test at a screening visit are not heigher/lower from 1,1*ULN/LLN (upper limit of normal/lower limit of normal) - indicators of clinical biochemical analysis at a screening visit: blood urea nitrogen, creatinine, glutamic-pyruvic transaminase, glutamate-oxaloacetate-transaminase, blood glucose test, creatinkinase, total protein, bilirubin are not heigher/lower from 1,1*ULN/LLN (upper limit of normal/lower limit of normal). Total cholesterol level from 3,6 mmol/L to 7,8 mmol/L. - absence of inflammatory or dystrophic myocardial changes based on ECG data. - absence of previous immunization with any vaccine against Ebola virus disease based on medical history data and during clinical trials as well Exclusion Criteria: - volunteer involvement in another study over the last 90 days - any immunization with vaccine over the last 30 days - presence of a concomitant illness in decompensation stage which might affect the course of the study (CNS organic lesion, decompensated cardiovascular diseases, any manifestations of kidney or acute liver failure, oncological diseases, diabetes mellitus) - subject has systolic blood pressure less than 100 mm Hg or greater than 139 mm Hg; diastolic blood pressure less than 60 mm Hg or greater than 90 mm Hg; heart rate lower than 60 beats per minute or above 90 beats per minute - any clinically significant laboratory abnormalities - subject has received treatment with steroids for the last 10 days - subject has received immunoglobulins or other blood products over the last 3 months - patient unwillingness to participate in the study - blood donation (at least 450 ml of blood or plasma) by subject in less than 2 months prior to the start of the study - subject has a history of the consumption of more than 5 units (0.25 l of pure alcohol) a week or drug abuse - subject smokes more than 10 cigarettes a day - positive results of urine test for narcotic drug residues - positive result of breath alcohol test (in the expired air sample) - subject has no ability to understand or follow the Protocol instructions - patient unwillingness to follow the procedures - pregnancy or breast feeding - subject has received immunosuppressive and/or immunomodulating agents within 6 months prior to the start of the study - history of regular injection or intranasal drug use; injection or intranasal drug use at the present time - subject has experienced symptoms of respiratory disease for the last 3 days - subject has exacerbation of allergic diseases or history of anaphylactic reactions or angioneurotic edema - previous history of hypersensitivity or allergic reactions to the administration of any vaccines - allergic reactions to the vaccine components |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Research Institute of Influenza | Sankt-Peterburg |
Lead Sponsor | Collaborator |
---|---|
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Research Institute of Influenza, Sankt-Peterburg, Russian Federation |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events | Determination of Number of Participants With Adverse Events | through the whole study, an average of 90 days | |
Primary | Number of Participants With Serious Adverse Events | Determination of Number of Participants With Serious Adverse Events | through the whole study, an average of 90 days | |
Primary | Number of Participants with Solicited Local and Systemic Adverse Events | Determination of Number of Participants with Solicited Local and Systemic Adverse Events | through the whole study, an average of 90 days | |
Primary | Antibody levels against the EBOV glycoprotein GP measured by an enzyme-linked immunosorbent assay (ELISA) | Determination of antibody levels against the EBOV glycoprotein GP measured by an ELISA vs. baseline values and placebo | at days 0, 21, 42, 28 and 90 | |
Secondary | Assessment of antigen-specific cell-mediated immune response | determination of specific T-cell- mediated response to Ebola virus proteins vs. baseline values and placebo | at days 0 and 28 | |
Secondary | Neutralizing antibody levels measured by a virus-neutralization assay | Determination of the neutralizing antibody titer for a virus in virus neutralization reaction vs. baseline values and placebo | at days 0 and 28 | |
Secondary | Change of the vital signs (systolic and diastolic blood pressure, heart rate, body temperature) after administration of the product | Evaluation of the product safety by assessing its impact on the vital signs (systolic and diastolic blood pressure, heart rate, body temperature) in healthy volunteers after administration of the product in comparison to placebo | through the whole study, an average of 90 days | |
Secondary | Change of the clinical laboratory test results after administration of the product | Evaluation of the product safety by assessing its impact on the clinical laboratory test results in healthy volunteers after administration of the product in comparison with placebo | through the whole study, an average of 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |